Management of influenza: Use of new antivirals and resistance in perspective

Clinical Drug Investigation

Volumn 20, Issue 6, 2000, Pages 447-454

  Jackson, Helen C ^a   Roberts, Noel ^a   Wang, Z Michael ^b   Belshe, Robert ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b GILEAD SCIENCES   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS MUTATION;

EID: 0034538794     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200020060-00007     Document Type: Review

References (38)

1. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized, controlled trial
3. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial
4. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infection
5. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
6. Assessment of antibiotic prescription in acute respiratory infections in adults
7. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding
8. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoro-acetylneuraminic acid (FANA): Mechanism of action
9. In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors
10. Structure of the catalytic and antigenic sites in influenza virus neuraminidase
11. Targeting influenza virus neuraminidase - A new strategy for antiviral therapy
12. The neuraminidase inhibitor oseltamivir is efficacious against A/Hong Kong/156/97 (H5N1) and H9N2 influenza virus
13. Characterization of influenza A/Hong Kong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice
14. Maximising benefits of influenza treatment with oral oseltamivir - Results of the IMPACT study
15. Oral oseltamivir treatment of influenza in children
16. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial
17. Zanamivir in the prevention of influenza among healthy adults
18. Use of the selective oral neuraminidase inhibitor oseltamvir to prevent influenza
19. Amantadine and rimantadine
20. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine
21. Implications of viral resistance to amantadine in control of influenza A
22. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
23. Emergence and possible resistance of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2)
24. Influenza virus resistance to neuraminidase inhibitors
25. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
26. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en
27. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
28. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
29. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor RWJ-270201
30. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
31. Monitoring of viral susceptibility: New challenges with the development of influenza NA inhibitors
32. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir [#P-326]
33. Resistance of influenza viruses to neuraminidase inhibitors - A review
34. Oseltamivir treatment of experimental influenza A/Texas/36/91 (H1N1) virus infection in humans: Selection of a novel neuraminidase variant
35. Oral oseltamivir in human experimental influenza B infection
36. An oseltamivir treatment-selected influenza A/N2 virus with a R292K mutation in the neuraminidase gene has reduced infectivity in vivo
37. An oseltamivir treatment-selected influenza A/Wuhan/359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo [#P-330]
38. Virological assessment in vitro and in vivo of an influenza H1N1 virus with a H274Y mutation in the neuraminidase gene